Additional file 1 of Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan

Additional file 1: Figure S1. Median overall survival of 527 PDAC patients with or without germline gene mutations in different stage. Figure S2. Median overall survival of 107 stage III PDAC patients with or without conversion surgery. Figure S3. Timeline comparison between the investigator-initiated trials for pancreatic cancer in Taiwan and the corresponding global phase III trials. Figure S4. The distribution of the most commonly used regimen by year. An arrow indicates the time of nab-paclitaxel reimbursement in Taiwan. Figure S5. Median overall survival of 320 PDAC patients with or without enrollment in clinical trials. Figure S6. (A) Median overall survival of 363 stage III/IV PDAC patients treated by different regimens. (B) Median overall survival of 363 stage III/IV PDAC patients with or without HR gene mutations treated with 1L platinum-based or non-platinum-based chemotherapy. Table S1. Categories of the 80 candidate cancer-associated genes analyzed for germline mutations in PDAC patients. Genes that have overlapping properties are listed only once and were classified as low-, moderate-, high- and recessive penetrance. Table S2. Pathogenic and likely pathogenic germline variants in susceptibility genes. Table S3. Family history of cancer in 527 PDAC patients. Table S4. Demographics of 32 patients with germline mutation in 12 homologous recombination genes treated with first-line platinum chemotherapy or non-platinum chemotherapy. Table S5. List of all regimen used in 368 stage III/IV PDAC patients.

附加文件1：图S1。527例胰腺导管腺癌（Pancreatic Ductal Adenocarcinoma, PDAC）患者伴或不伴种系基因突变者在不同临床分期中的中位总生存期。图S2。107例III期胰腺导管腺癌患者伴或不伴转化手术者的中位总生存期。图S3。台湾地区胰腺癌研究者发起临床试验与对应全球III期临床试验的时间线对比。图S4。按年份统计的最常用治疗方案分布情况，箭头标注台湾地区白蛋白结合型紫杉醇（nab-paclitaxel）纳入医保报销的时间节点。图S5。320例胰腺导管腺癌患者伴或不伴临床试验入组者的中位总生存期。图S6。(A) 363例III/IV期胰腺导管腺癌患者接受不同治疗方案后的中位总生存期；(B) 363例III/IV期胰腺导管腺癌患者中，伴或不伴同源重组（Homologous Recombination, HR）基因突变者分别接受一线铂类或非铂类化疗后的中位总生存期。表S1。针对胰腺导管腺癌患者种系基因突变分析的80个候选癌相关基因分类。具有重叠特性的基因仅列出一次，并按低外显率、中等外显率、高外显率及隐性外显率进行归类。表S2。易感基因中的致病性及可能致病性种系变异。表S3。527例胰腺导管腺癌患者的癌症家族史情况。表S4。32例携带12个同源重组基因种系突变的患者，分别接受一线铂类化疗或非铂类化疗的人口统计学特征。表S5。368例III/IV期胰腺导管腺癌患者所使用的全部治疗方案列表。